Fact sheet: BB Biotech

Fund information

Fund name
BB Biotech B USD
Fund company manager
Bellevue Asset Management
Fund type
SIB
Fund manager(s)
Felicia Flanigan
since 31/08/2011
Dr.Tazio Storni
since 31/08/2011
Dallas Webb
since 31/08/2011
Lydia Bänziger
since 02/01/2012
Dr.. Daniel Koller
since 31/03/2009
Fund objective
The Fund’s investment objective is to generate attractive and competitive capital growth in the long term. It is therefore particularly suited to investors with an investment horizon of at least 5 years who want to selectively diversify their portfolio with investments in the biotechnology sector and who are willing to accept the equity risks typical of this sector.
Benchmark
Nasdaq Biotech Index
Investment style
Active,Growth
Investment method
Shares

Quick stats

1 Year return

26.35 %

1 Year rank in sector

4/30

Sector

FO Equity - Pharma Health & Biotech

Yield
-
Fund size

£ 59.9 m

FE Risk score

238

NAV
-
Discount/Premium
-
Gearing
-

Top in sector

Holdings snapshot

  • USA
    94.8%
  • Money Market
    4.1%
  • Others
    1.1%
  • Health Care
    55.1%
  • Healthcare & Medical Products
    14.6%
  • Pharmaceuticals
    13.8%
  • Others
    8.2%
  • Biotechnology/Medical
    4.2%
  • US Equities
    94.8%
  • Money Market
    4.1%
  • International Equities
    1.1%

Performance vs. Sector

Cumulative performance

1m6m1y3y5y
Fund-0.09 %13.22 %26.17 %11.11 %134.07 %
Sector1.39 %7.55 %14.37 %21.85 %103.82 %
Rank within sector26 / 316 / 314 / 3022 / 285 / 24
Quartile th4 th1 st1 st4 th1 st

Calendar performance

YTD-20172016201520142013
Fund27.46 %-24.69 %7.63 %36.33 %63.75 %
Sector16.98 %-9.92 %7.24 %28.08 %41.03 %
Rank within sector5 / 3030 / 3014 / 287 / 253 / 24
Quartile th1 st4 th2 nd2 nd1 st

Risk statistics

Alpha-3.79
Beta1.61
Sharpe0.06
Volatility26.64
Tracking error13.99
Information ratio-0.11
R-Squared0.86

Price movement

52 week high483.06
52 week low338.96
Current bid price0
Current offer price0
Current mid price470.53

Holdings by region

  • 94.8% USA
  • 4.1% Money Market
  • 1.1% Others

Holdings by sector

  • 55.1% Health Care
  • 14.6% Healthcare & Medical Products
  • 13.8% Pharmaceuticals
  • 8.2% Others
  • 4.2% Biotechnology/Medical
  • 4.1% Money Market

Holdings by asset type

  • 94.8% US Equities
  • 4.1% Money Market
  • 1.1% International Equities

Individual holdings

  • 8.7% CELGENE CORP
  • 8.3% GILEAD SCIENCES INC
  • 7.7% BIOGEN INC
  • 7.1% AMGEN INC
  • 6.9% REGENERON PHARMACEUTICALS INC
  • 4.6% ALEXION PHARMACEUTICALS INC
  • 4.3% VERTEX PHARMACEUTICAL
  • 4.2% ILLUMINA INC
  • 3.5% INCYTE CORP
  • 2.3% BIOMARIN PHARMACEUTICAL